Bharat Immunologicals & Biologicals (BOM:524663) Total Receivables: ₹100.26 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524663 Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
4 GF Score
Price ₹15.38
View Full Analysis

What is Bharat Immunologicals & Biologicals Total Receivables?

Bharat Immunologicals & Biologicals BOM:524663 -0.58% 4 Total Receivables is ₹100.26 Mil as of Sep. 2023. GuruFocus rates BOM:524663 with a GF Score™ of 4/100.

Bharat Immunologicals & Biologicals's Total Receivables for the quarter that ended in Sep. 2023 was ₹100.26 Mil.

Bharat Immunologicals & Biologicals Total Receivables Related Terms

Bharat Immunologicals & Biologicals Total Receivables Historical Data

* Premium members only.

The historical data trend for Bharat Immunologicals & Biologicals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Immunologicals & Biologicals Total Receivables Chart

Bharat Immunologicals & Biologicals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 734.24 188.01 29.35 43.76 178.16

Bharat Immunologicals & Biologicals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.77 0.00 178.16 0.00 100.26
BOM:524663
4GF Score
Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bharat Immunologicals & Biologicals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹100.26 Mil mean?
Bharat Immunologicals & Biologicals (BOM:524663) has a Total Receivables of ₹100.26 Mil as of Sep. 2023. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bharat Immunologicals & Biologicals and its competitors.
Is Bharat Immunologicals & Biologicals' Total Receivables too high?
Bharat Immunologicals & Biologicals' current Total Receivables is ₹100.26 Mil. Overall, Bharat Immunologicals & Biologicals has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Bharat Immunologicals & Biologicals' Total Receivables compare to VRTX and REGN?
Bharat Immunologicals & Biologicals' Total Receivables of ₹100.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bharat Immunologicals & Biologicals and its competitors. Bharat Immunologicals & Biologicals's current Total Receivables is ₹100.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Immunologicals & Biologicals stock overvalued right now?
Bharat Immunologicals & Biologicals (BOM:524663) has a current Total Receivables of ₹100.26 Mil. The current Total Receivables is ₹100.26 Mil. Bharat Immunologicals & Biologicals' overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bharat Immunologicals & Biologicals (BOM:524663), the current Total Receivables is ₹100.26 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bharat Immunologicals & Biologicals Business Description

Address Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203
Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.
4GF Score

Get the complete analysis for BOM:524663

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹15.38
Price